

DIA-KMTC MedTech Conference – 2026

Advancing Medical Technology from Innovation to Impact

Theme: Concept to Care – Safe, Smart, and Scalable MedTech

📅 May 21-22, 2026 | 📍 O by Tamara, Thiruvananthapuram, Kerala, India

OVERVIEW

The DIA-KMTC MedTech Conference – 2026, to be held in Kerala in collaboration with the [Kerala Medical Technology Consortium \(KMTC\)](#), is a focused single track, two-day conference designed to address the rapidly evolving MedTech landscape in India and globally.

Building on the momentum of the DIA MedTech Conference 2025, this conference will bring together *regulators, industry leaders, innovators, clinicians, and academia* to discuss the end-to-end lifecycle of *Medical Devices, Digital Health Technologies, Diagnostics, Software as a Medical Device (SaMD), and Combination Products*.

The program will emphasize *quality, regulatory science, innovation enablement, clinical evidence, and market access*, with a strong focus on practical insights, policy alignment, and future-ready capabilities.

WHAT TO EXPECT

Learning Objectives

By attending this conference, participants will be able to:

- Understand current and emerging regulatory expectations for MedTech, SaMD, diagnostics, and combination products
- Gain clarity on clinical evidence, safety, performance, and lifecycle management requirements
- Explore digital transformation, AI-enabled MedTech, and data-driven decision-making
- Learn best practices in quality systems, risk management, and post-market surveillance
- Identify pathways to accelerate innovation while ensuring patient safety and compliance

Key Priority Science Topics

DIA MedTech Conference 2026 will focus on priority science and regulatory domains critical to enabling quality-driven innovation and global market access for medical devices, in vitro diagnostics, combination products, and Software as a Medical Device (SaMD). Sessions are designed to address real-world regulatory expectations, compliance challenges, and execution best practices across highly regulated markets.

- Quality & Compliance Excellence
- Regulatory Pathways for Global Market Access
- Clinical Evidence & Performance Evaluation
- Risk, Safety & Human Factors Engineering
- Digital, Software & AI-Enabled Medtech
- Advanced Manufacturing & Export Readiness
- Business Insight, Leadership & Talent

Together, these topics deliver a structured, end-to-end learning experience, spanning science, regulation, manufacturing, and leadership, equipping MedTech stakeholders to build trusted, globally competitive products with patient safety at the core.

Who Should Attend

The **DIA MedTech Conference 2026** is designed for professionals involved in the development, testing, regulation, and commercialization, and end users of medical devices, in vitro diagnostics, combination products, and Software as a Medical Device (SaMD).

- MedTech, Medical Device, and Diagnostics industry professionals
- Quality, Regulatory Affairs, Clinical, and R&D leaders
- Digital Health, SaMD, AI/ML solution developers
- Clinicians, biomedical engineers, and hospital technology leaders
- Start-ups, innovators, and MedTech entrepreneurs
- CDSCO and State regulatory stakeholders
- Academia, research institutions, and policy influencers.

PROGRAM COMMITTEE



C. Palani
Palaniappan, Ph.D
CEO, Aridica,
Corporation, USA,
DIA Board Member



C. Padmakumar
Special Officer
Kerala Medical
Technology
Consortium (KMTC)



**Balagopal
Chandrasekhar**
Chairman, Kerala
State Industrial
Development
Corporation (KSIDC)



**Sridevi
Nagarajan, Ph.D**
Founder & Director,
AyusArogya Ltd. DIA
Communities Chair
for AI in Healthcare



**Satheesan B. MS,
DNB, MCh (Surg.
Oncology)**
Director, Malabar
Cancer Centre,
Thalassery, Kerala



Sinto Poulouse
Director, Iqzyme
Medtech Pvt. Ltd



Manoj A
Independent
Consultant. Former
VP & Director,
Terumo Penpol



Rohit Philip
Senior Program
Consultant, Kerala
Medical Technology
Consortium (KMTC)



Chetan Makam
GM, Terumo BCT.
Managing Director &
Board Chair,
Terumo Penpol

SPEAKERS



Gregory Smith
Country Director,
FDA India, US
Embassy. US FDA



B.V.R. Mohan Reddy
Founder Chairman,
Cyient Group.
Chairman, Board of
Governors, IIT
Hyderabad. Founding
Director, T-Hub



R S Raghuvanshi
Drug Controller
General of India
(DCGI), CDSCO



Pooja Jani
Medical Officer,
Diagnostic Data
Program; CDRH,
US FDA



**Mohammed Y
Safirulla K**
IAS, Director, IndiaAI
Mission, MeitY,
Government of India



Mrutyunjay Suar
Chairman, BCKIC.
CEO, KIIT-TBI.
Director General III,
KIIT University



**P.S. Chandranand
Ph.D**
Consultant - WHO
Prequalification.
Director, Iqzyme
Medtech Pvt. Ltd.



Sreejith Viswam
Director, Innovation
Enablers, Stryker
Global Technology
Center, India



Sarada Jayakrishnan
General Manager,
Terumo Penpol



Rupam Chaudhury
Global Business
Head, Medical,
Lifesciences and
Healthcare, LTTS



Gurpreet Singh
VP, Managing
Director Integrated
Safety, IQVIA, UK



Adarsh Srivastava
Head of IVD Data
Insights - Data,
Analytics & Research,
Roche



Atonu Dutta
Founder and CEO,
Neujin Solutions



Jaydeep Ruparelia
Founder and CEO,
Infopercept

AGENDA: Day 1, 21 May 2026; Thursday

8:00 – 9:00 AM **Registration and Welcome Coffee**

9:00 – 9:05 AM **Welcome Remarks from DIA [5 min]**

Ashok Kumar Swain, General Manager & Executive Director - DIA (India)

9:05 – 9:10 AM **Welcome Remarks from KMTC [5 min]**

C. Padmakumar, Special Officer, Kerala Medical Technology Consortium (KMTC)

9:10 – 9:20 am **Meeting Opening Remarks by Program Chair [10 min]**

Balagopal Chandrasekhar, Chairman, Kerala State Industrial Development Corporation (KSIDC)

9:20 – 9:30 am **Opening Address by USFDA [10 min]**

Gregory Smith, Country Director - FDA India - US Embassy, New Delhi

9:30 – 9:40 am **Opening Address [10 min]**

R S Raghuvanshi, Drug Controller General of India (DCGI), CDSCO

9:40 – 10:00 am **Opening Address [20 min]**

B.V.R. Mohan Reddy, Founder Chairman, Cyient Group. Chairman, Board of Governors, IIT Hyderabad. Founder Director, T-Hub.

10:00-11:15AM **Session 1: The Regulatory Maze: Mapping Pathways to India, EU, and US Market Access**

Session Chair: Sinto Poullose, Director at IQZYME MEDTECH PVT. LTD

Session Focus: A practical navigation session on US FDA, EU MDR, and India's CDSCO regulatory routes—how to choose the right pathway, avoid common and avoidable delays, and build a regulatory strategy aligned with your product type, risk class, and target market timelines. Expect concrete do's and don'ts from real submissions, approval journeys, and market-entry playbooks across mature and emerging markets.

10:00-10:15 AM **S1.T1: Keynote Presentation [15 min]**

Pooja Jani, MD, MPH, Medical Officer, Diagnostic Data Program; Center for Devices and Radiological Health (CDRH), U.S. Food & Drug Administration (US FDA)

10:15-10:30AM **S1.T2: Keynote Presentation [15 min]**

Aseem Sahu, Deputy Drug Controller (DDC), Medical Device Division, CDSCO (HQ) - TBC

10:30-11:15AM **S1.T3: Panel Discussion [45 min]**

Moderator: P.S. Chandranand Ph.D, WHO Prequalification Consultant. Director, Iqzyme Medtech

Panelists: Speakers with the additional presence of

3. MHRA speaker – TBC

4. **Sujit Kumar**, Drug Controller- Kerala State FDA

5. **Sreejith Viswam**, Director- Director- Innovation Enablers (RAQA, R&D Test Lab and R&D Operations), Stryker Global Technology Center, India

6. **Jayant SK**, Sr General Manager, TUV SUD - TBC

11:15-11:45AM

Tea / Coffee & Networking Break

11:45-1:00PM **Session 2: Safe & Sure - Clinical Evidence & Performance Evaluation**

Session Chair: Satheesan B, M.S, DNB, MCh (Surg Oncology). Director, Malabar Cancer Centre (Postgraduate Institute of Oncology Sciences and Research)

Session Focus: What “good evidence” actually means—and how to generate it efficiently. Covers performance evaluation logic, clinical evidence expectations, endpoints, study design choices, and

documentation that stands up to scrutiny—so you don't over-invest where it doesn't add value, or under-invest and get stuck.

11:45-12:00 PM **S2.T1: Presentation: Changing paradigms in Clinical trials and validation of MedTech [15 min]**
Anju Gopan, Director Medical Affairs, IQVIA - TBC

12:00-12:15 PM **S2.T2: Presentation: Clinical Evaluation and Validation of Med Tech devices- Strengths and Challenges in India [15 min]**
Atonu Dutta, Founder and CEO, Neujin Solutions

12:15 – 1:00 PM **S2.T3: Panel Discussion: Building Trust in MedTech - Ensuring Safety, Clinical Evidence, and Performance in India [45 min]**
Moderator: Satheesan B, Director, Malabar Cancer Centre
Panelists: Speakers with the additional presence of
3. **Gurpreet Singh**, Vice President, Managing Director Integrated Safety, IQVIA
4. **Dr E. Sreekumar**, Directors, Institute of Advance Virology – TBC
5. **Dr. Vijayakumar Manavalan, MBBS, MS, MCh (Surg Oncology)**, Pro chancellor, Yenapoya university. Former Director of KIDWAI Memorial Institute of Oncology, Bangalore

1:00-2:00PM **Lunch Break**

2:00-3:30PM **Session 3: 🌐 World Café: Breaking Barriers to Global Medtech Success**
Session Chair: Rohit Philip, Senior Program Consultant, Kerala Medical Technology Consortium (KMTC)
Session Focus: An outcome-led, structured discussion format to surface the real blockers across regulation, evidence, quality systems, digital trust, talent, and export readiness—and convert them into an actionable set of ecosystem recommendations. Less “panel talk,” more field intelligence + solutions capture.

2:00-3:00PM **S3.T1: Activity [60 min]**
All delegates

3:00-3:30PM **S3.T2: Presentation by each Facilitators [30 min]**
The Table Facilitators

3:30-4:00PM **Tea/Coffee & Networking Break**

4:00-5:30PM **Session 4: Quality Leadership — Building Inspection-Ready, Scalable Compliance**
Session Chair: Manoj A, Independent Consultant, Former Vice President & Director - Global Product Development and Engineering, Terumo Penpol Pvt Ltd.
Session Focus: How to move from “audit preparation” to quality as a leadership system. Focus on ISO 13485 alignment, CAPA discipline, supplier controls, data integrity, design controls, and creating a culture where quality accelerates speed-to-market instead of slowing it down.

4:00-4:15PM **S4.T1: Presentation: Redefining Quality: FDA's Alignment with ISO 13485 and Its Impact on Manufacturers [15 min]**
Rupam Chaudhury, Global Business Head, Medical, Lifesciences and Healthcare, L&T Technology Services (LTTTS)

4:15-4:30PM **S4.T2: Presentation: Beyond compliance - Quality as a leadership system [15 min]**
Sreejith Viswam, Director- Innovation Enablers (RAQA, R&D Test Lab and R&D Operations), Stryker Global Technology Center, India

4:30-5:30PM **S4.T3: Panel Discussion [60 min]**
Moderator: Manoj A, Independent Consultant
Panelists: Speakers with the additional presence of
3. **Sarada Jayakrishnan**, General Manager - Quality, Terumo Penpol Pvt Ltd
4. **P. S. Chandranand**, WHO Prequalification Consultant. Director, Iqzyme Medtech Pvt. Ltd
5. **Jayant SK**, Sr General Manager, TUV SUD – TBC
6. **Srihariraju Manthena**, Service delivery Manager-BSI India Regulatory Services

AGENDA: Day 2, 22 May 2026; Friday

9:00 – 9:05 AM **Welcome & Recap of Day 2 – DIA [5 min]**

Program Chair / DIA

9:05 – 9:15 AM **D2.KNA 1: Keynote Address [10 min]**

C. Palani Palaniappan, Ph.D, CEO, Aridica Corporation, USA, **DIA Global Board of Directors**

9:15- 9:30 AM **D2. KNA 2: Keynote Address [15 min]**

Mohammed Y Safirulla K, IAS, Director, IndiaAI Mission. Ministry of Electronics and Information Technology, Government of India

9:30-11:00AM

Session 5: Navigating the AI Frontier in MedTech: From SaMD to AI-Driven Drug Development

Session Chair: Sridevi Nagarajan, Founder & Director, AyusArogya Ltd. DIA Communities Chair for AI in Healthcare.

Session Focus: The global MedTech environment for medical AI has reached a decisive turning point. Topics addressed include SaMD classification under the EU AI Act and FDA guidance; AI applications in drug development and MedTech innovation; validation and lifecycle control for adaptive algorithms; cybersecurity obligations; post-market surveillance; and a multi-jurisdictional regulatory strategy spanning the FDA, EMA, MHRA, and CDSCO. A panel discussion covering the future of AI in MedTech and what it means for India.

9:30-09:45 AM **S5.T1: Presentation: The Regulatory Landscape in 2026 [15 min]**

MHRA speaker – TBC

09:45 -10:00AM **S5.T2: Presentation: AI in Drug Development & MedTech Innovation [15 min]**

Adarsh Srivastava, Head of IVD Data Insights - Data, Analytics & Research, Roche, India

10:00-10:15AM **S5.T3: Presentation: Validation, Cybersecurity & Lifecycle Control [15 min]**

Jaydeep Ruparelia, Founder and CEO, Infopercept

10:15-11:00AM **S5.T4: Panel Discussion: Future of AI in Medtech [45 min]**

Moderator: Sridevi Nagarajan, Founder & Director, AyusArogya Ltd. DIA Communities Chair for AI in Healthcare.

Panelists: Speakers with the additional presence of

4. **Rohit Philip**, Senior Program Consultant, KMTC
5. **Mohammed Y Safirulla K**, IAS, Director Ministry of Electronics and Information Technology, Government of India and Director, IndiaAI Mission
6. US FDA expert – TBC

11:00-11:30AM

Tea/Coffee & Networking Break

11:30-1:00PM

Session 6: Creating a Business, Leadership & Talent Ecosystem for Global Medtech

Session Chair: Chetan Makam, General Manager, Global Blood Solutions - Terumo Blood and Cell Technologies, and Managing Director & Board Chair - Terumo Penpol

Session Focus: Creating a Business, Leadership & Talent Ecosystem for Global Medtech is about building what works on the ground. This session looks at how leaders design systems that scale MedTech innovations in complex, regulated markets while hard wiring resilience into supply chains for medical plastics and electronics. We will explore how to architect robust RA/QA and clinical capabilities, enable fast, fact-based decisions under uncertainty, and orchestrate cross-functional teams that deliver consistently at global scale. We will also dig into building a services and talent ecosystem—attracting, growing, and retaining people who can think beyond products, partner deeply with suppliers, de-risk critical component and create an ecosystem into sustainable competitive advantage in MedTech.

11:30-12:00PM **S6.T1: Keynote Presentation [30 min]**

Dr Jitendra Sharma, CEO, AMTZ - Virtual

12:00 – 1:00 PM **S6.T2: Panel Discussion Title [60 min]**

Moderator: Chetan Makam, General Manager– Terumo BCT, and MD & Board Chair - Terumo Penpol

Panelists: Speakers with the additional presence of

2. **Vivek Shah**, CEO, Meril - TBC

3. **Mrutyunjay Suar**, CEO at KIIT-TBI. Director General Industry-Institute-Innovation-Interface at KIIT University. Chairman of BCKIC.

4. **Gurpreet Singh**, Vice President, Managing Director Integrated Safety, IQVIA, UK

1:00-2:00PM

Lunch Break

2:00-3:30PM

Session 7: Manufacturing as the Secret Weapon- Advanced Manufacturing & Export Readiness

Session Chair: C. Padmakumar, Special Officer, Kerala Medical Technology Consortium (KMTC)

Session Focus: Manufacturing maturity is a market access advantage. Covers process validation, tech transfer, supplier qualification, traceability, scale-up discipline, and how to translate manufacturing strength into regulatory confidence and buyer trust—especially for export markets.

2:00-2:20PM

S7.T1: Keynote Presentation [20 min]

2:20-2:40PM

S7.T2: Keynote Presentation [20 min]

Neil Bonzagni, Acting Deputy Director, US FDA India Office

2:40-3:30PM

S7.T3: Panel Discussion Title [50 min]

Moderator: C. Padmakumar, Special Officer, KMTC

Panelists: Speakers with the additional presence of

3. **P.S. Chandranand**. WHO Prequalification Consultant, Director, Iqzyme Medtech.

4. **B. Harikrishnan**, General Manager, Terumo Penpol

5. **Aniraj Radhakrishnan**, General Manager, SFO Technologies

3:30-4:00PM

Closing Remarks & Vote of Thanks

Program Chair
KMTC
VoT – DIA

4:00-5:30PM

Tea & Networking

Strategic Partner



Media Partner



PAYMENT INFORMATION

Meeting registration for an individual participant with **ONLINE payment** can be completed directly through the DIA website. To register online for **DIA MedTech Conference 2026**, [Click Here](#).

For group registrations, please contact the meeting manager (below table).

BANK ACCOUNT details for other modes of payment:

Account Name: DIA (INDIA) PRIVATE LIMITED
Account No: 061010200024611
Bank Name: AXIS BANK LIMITED
Branch Name: Dhiraj Baug, Near Hari Niwas Circle,
LBS Marg, Thane (W) – 400602
IFSC Code: UTIB0000061 MICR Code: 400211013
Swift Code: AXISINBB061

Add Membership for Instant Discounts

Join DIA today to enjoy discounted meeting registration fees and unlock all membership benefits. Visit www.diahome.org and select the “Membership” option under the “Get Involved” tab for more details. Select the ‘Add Membership’ option during registration to instantly avail membership discount on the registrations fee.

REGISTRATION FEES:

Category	Advance Rate (until April 21 st)	Standard Rate (from 22 nd April)
Industry – Member	INR 10,500 + GST	INR 13,000 + GST
Industry – Non-member	INR 13,000 + GST	INR 15,000 + GST
Academia*/ Non-Profit / Govt – Member	INR 5,000 + GST	DIA Membership Fee Discounts: 71% off for students (₹ 1,970 + GST) 50% off for academia/government (₹ 3,397 + GST)
Academia*/ Non-Profit / Govt – Non-member	INR 8,000 + GST	

For Group Registrations: Please contact meeting manager. Email: nishank.nivedit@diaglobal.org | Mob: +91 8178837734

DIA Cancellation & Refund Policy :

- Cancellation Deadline:** Cancellations must be submitted in writing and received by 60 days before the meeting to qualify for a refund. Cancellations received after this date will not be eligible for any refund.
- Transfer Policies:** Registrations may be transferred to a colleague at any time, but membership benefits are non-transferable. Please notify the DIA India office in writing. Substitute registrants will be charged any applicable non-member fees at the rate in effect on the transfer date.
- No-Shows and Late Cancellations:** Registrants who do not cancel in writing by the deadline and do not attend the event will remain liable for the full registration fee. No refunds will be issued under such circumstances.
- Administrative Fee:** A 25% administrative fee will be deducted from all eligible refunds.
- Force Majeure:** DIA reserves the right to alter the venue or the date. In the event of cancellation or postponement due to circumstances beyond DIA's control (including but not limited to natural disasters, public health emergencies, government restrictions, or strikes), DIA shall not be held liable for any resulting costs or damages, and refunds may be partially or fully waived at DIA's discretion.
- Travel and Accommodation Liability:** DIA is not responsible for any airfare, hotel, or travel-related expenses incurred by participants. These arrangements are the sole responsibility of the registrant.
- Refund Processing and Currency Disclaimer:** Eligible refunds will be processed within 60 business days after the conclusion of the event. Refunds will be made in the original transaction currency, and DIA will not be liable for any bank charges or currency fluctuations.

DIA REGISTRATION FORM

PLEASE PRINT ALL INFORMATION CLEARLY

Dd Month 2025

Please check the applicable **category**: Industry Government Academia Student

Last Name

First Name

Middle Initial

Please check one:

Mr. Ms. Dr. Prof.

Job Position

Name of Organization (Primary Affiliation)

Address: (As per your country's format))

City

Postal Code

Country

Home
 Business

Mobile Number (Required)

Telephone Number

Email (Required for confirmation)

If sending this form by post or courier, please provide a copy of the registrant's business card.

CHEQUE / DRAFT

Completed form, along with draft/cheque made payable to DIA (India) Private Limited should be sent to:

Vinita Shetty | Finance Manager

DIA (India) Pvt. Ltd.
Cowork30, Office #201, ACME Plaza-2, Chakala
Andheri- Kurla Road, Andheri (East), Mumbai – 400059

Email: vinita.shetty@diaglobal.org. Cell: +91 9769764645

PRIVACY POLICY

DIA respects the privacy of all its members and customers. To view our policy, click the link below: <https://www.diaglobal.org/en/about-us/privacy-policy>. You agree that your personal data will be transferred to DIA in the US.

*Academia Category

The ACADEMIA category applies to individuals with primary, full-time affiliation to a bona fide academic institution, and includes STUDENTS. Proof of appointment or enrollment is required.